- Home
- NRXS vs NSRX Comparison
NRXS vs NSRX Comparison
Compare NRXS & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | NSRX |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 53.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NRXS | NSRX |
|---|---|---|
| Price | $5.32 | $6.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.00 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 83.5K | 4.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.05 | N/A |
| Revenue Next Year | $146.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $4.90 |
| 52 Week High | $6.20 | $9.99 |
Technical Indicators
Market Signals| Indicator | NRXS | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.54 | 52.58 |
| Support Level | $4.50 | $4.90 |
| Resistance Level | $4.50 | $6.47 |
| Average True Range (ATR) | 0.38 | 0.47 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 100.00 | 95.54 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.